Ken Herrmann

33.3k total citations · 10 hit papers
586 papers, 19.0k citations indexed

About

Ken Herrmann is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ken Herrmann has authored 586 papers receiving a total of 19.0k indexed citations (citations by other indexed papers that have themselves been cited), including 341 papers in Radiology, Nuclear Medicine and Imaging, 254 papers in Pulmonary and Respiratory Medicine and 181 papers in Oncology. Recurrent topics in Ken Herrmann's work include Radiopharmaceutical Chemistry and Applications (171 papers), Medical Imaging Techniques and Applications (167 papers) and Prostate Cancer Treatment and Research (144 papers). Ken Herrmann is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (171 papers), Medical Imaging Techniques and Applications (167 papers) and Prostate Cancer Treatment and Research (144 papers). Ken Herrmann collaborates with scholars based in Germany, United States and Italy. Ken Herrmann's co-authors include Wolfgang P. Fendler, Andreas K. Buck, Markus Schwaiger, Bernd J. Krause, Johannes Czernin, Constantin Lapa, Wolfgang Weber, Matthias Eiber, Hans‐Jürgen Wester and Boris Hadaschik and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Ken Herrmann

565 papers receiving 18.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2021 1.5k citations Oliver Sartor, Johann S. de Bono et al. profile →
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

2017 567 citations Wolfgang P. Fendler, Thomas A. Hope et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

2007 550 citations Florian Lordick, Katja Ott et al. profile →
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

2017 386 citations Matthias Eiber, Ken Herrmann et al. Journal of Nuclear Medicine profile →
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

2021 214 citations Johannes Czernin, Michael S. Hofman et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
Radiotheranostics in oncology: current challenges and emerging opportunities

2022 209 citations Ken Herrmann et al. profile →
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

2023 127 citations Robert Seifert, Ken Herrmann et al. European Urology profile →
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds

2022 114 citations Manuel Weber, Mark Konijnenberg et al. European Journal of Nuclear Medicine and Molecular Imaging profile →
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

2024 113 citations Ken Herrmann et al. profile →
Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches

2023 80 citations Ken Herrmann, Boris Hadaschik et al. Cancers profile →

Peers

Countries citing papers authored by Ken Herrmann

Since Specialization

Citations

This map shows the geographic impact of Ken Herrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Herrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Herrmann more than expected).

Fields of papers citing papers by Ken Herrmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Herrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Herrmann. The network helps show where Ken Herrmann may publish in the future.

Co-authorship network of co-authors of Ken Herrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Herrmann. A scholar is included among the top collaborators of Ken Herrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Herrmann. Ken Herrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimizing theranostics chatbots with context-augmented large language models 2025 ·Theranostics ·(unknown), (unknown), (unknown), Robert Seifert, (unknown), George Prenosil, Mike Sathekge, Ken Herrmann, Richard P. Baum, Wolfgang Weber, Axel Rominger, Kuangyu Shi	1
2	Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy inEGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance 2024 ·Journal of Nuclear Medicine ·Martin Schüler, J. Hense, Kaid Darwiche, Sebastian Michels, Hubertus Hautzel, Carsten Kobe, Smiths Lueong, Martin Metzenmacher, Thomas Herold, (unknown), (unknown), Alexander Drzezga, Dirk Theegarten, Felix Nensa, Jürgen Wolf, Ken Herrmann, Marcel Wiesweg	3
3	[¹⁷⁷Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal Carcinoid 2024 ·Journal of Nuclear Medicine ·Akram Al‐Ibraheem, Ahmed Saad Abdlkadir, (unknown), Ken Herrmann	0
4	Prognostic Implications of⁶⁸Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors 2024 ·Journal of Nuclear Medicine ·Masao Watanabe, Wolfgang P. Fendler, Hong Grafe, Nader Hirmas, Rainer Hamacher, (unknown), Kim M. Pabst, Hubertus Hautzel, Clemens Aigner, Stefan Kasper, Bastian von Tresckow, Martin Stuschke, Sherko Kümmel, (unknown), Boris Hadaschik, Viktor Grünwald, Fadi Zarrad, Jens T. Siveke, Ken Herrmann, Manuel Weber	9
5	EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose–response and threshold absorbed doses 2024 ·European Journal of Nuclear Medicine and Molecular Imaging ·Jean‐Pierre Pouget, Pablo Mínguez Gabiña, Ken Herrmann, Désirèe Deandreis, Mark Konijnenberg, David Taïeb, Fijs W. B. van Leeuwen, Jens Kurth, Uta Eberlein, Michael Laßmann, Katharina Lueckerath, (unknown)	4
6	Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial 2024 ·European Urology ·Andrew J. Armstrong, Oliver Sartor, Johann S. de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, (unknown), (unknown), Michael J. Morris	7
7	EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials 2024 ·European Journal of Nuclear Medicine and Molecular Imaging ·Caroline Stokke, Silvano Gnesin, Johannes Tran‐Gia, Francesco Cicone, Søren Holm, Marta Cremonesi, (unknown), Thomas Wendler, Nic Gillings, Ken Herrmann, Felix M. Mottaghy, Jonathan Gear	15
8	Superior Tumor Detection for⁶⁸Ga-FAPI-46 Versus¹⁸F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma 2023 ·Journal of Nuclear Medicine ·Kim M. Pabst, Marija Trajkovic‐Arsic, Phyllis F. Cheung, Simone Ballke, Katja Steiger, (unknown), Benedikt M. Schaarschmidt, Aleksandar Milošević, Robert Seifert, Michael A. Nader, Lukas Kessler, Jens T. Siveke, Katharina Lueckerath, Stefan Kasper, Ken Herrmann, Nader Hirmas, Hartmut Schmidt, Rainer Hamacher, Wolfgang P. Fendler	32
9	Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·Moon Kim, Robert Seifert, (unknown), David Kersting, (unknown), (unknown), Kelsey L. Pomykala, Jan Egger, Wolfgang P. Fendler, Ken Herrmann, Jens Kleesiek	12
10	Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy 2023 ·Journal for ImmunoTherapy of Cancer ·(unknown), Claudia Kesch, Wolfgang P. Fendler, (unknown), Yang Liu, (unknown), Elai Davicioni, Jason D. Hughes, Hong Song, Katharina Lueckerath, Ken Herrmann, Boris Hadaschik, Robert Seifert	4
11	Next generation radiotheranostics promoting precision medicine 2023 ·Annals of Oncology ·Kelsey L. Pomykala, Boris Hadaschik, Oliver Sartor, Silke Gillessen, Christopher J. Sweeney, Tim Maughan, Michael S. Hofman, Ken Herrmann	42
12	A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer Patients 2023 ·Cancers ·(unknown), Wolfgang P. Fendler, Paolo Castellucci, Christoph Berliner, Francesco Barbato, Ken Herrmann, Andrea Farolfi, Stefano Fanti	1
13	Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response 2023 ·Molecular Cancer Research ·(unknown), (unknown), Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, Diane S. Abou, (unknown), Norbert Peekhaus, Robert J. Klein, Robert Damoiseaux, Steven M. Larson, Hans Lilja, Daniel L.J. Thorek, David Ulmert	2
14	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities 2022 ·Clinical Cancer Research ·Wolfgang P. Fendler, Kim M. Pabst, Lukas Kessler, Pedro Fragoso Costa, Justin Ferdinandus, Manuel Weber, (unknown), Katharina Lueckerath, Lale Umutlu, (unknown), (unknown), Martin Schüler, Marit Ahrens, Christoph Rischpler, Sebastian Bauer, Ken Herrmann, Jens T. Siveke, Rainer Hamacher	91
15	Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis 2022 ·Journal of Nuclear Cardiology ·Lukas Kessler, Pedro Fragoso Costa, David Kersting, Walter Jentzen, (unknown), (unknown), Alexander Carpinteiro, (unknown), Tim Hagenacker, Andreas Thimm, Tienush Rassaf, Ken Herrmann, Μαρία Παπαθανασίου, Christoph Rischpler	23
16	Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer 2022 ·Cancers ·Lale Umutlu, Julian Kirchner, Nils Martin Bruckmann, Janna Morawitz, Gerald Antoch, Saskia Ting, Ann‐Kathrin Bittner, Oliver Hoffmann, (unknown), Eugen Ruckhäberle, Onofrio A. Catalano, (unknown), Johannes Grueneisen, Harald H. Quick, Wolfgang P. Fendler, Christoph Rischpler, Ken Herrmann, Peter Gibbs, Katja Pinker	31
17	18F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET? 2020 ·Journal of Clinical Medicine ·Yan Li, (unknown), (unknown), Stefanie Bertram, Benedikt M. Schaarschmidt, Aydın Demircioğlu, Johannes Ludwig, Julian Kirchner, Christoph Rischpler, Ken Herrmann, Onofrio A. Catalano, Lale Umutlu	12
18	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer 2019 ·Clinical Cancer Research ·Wolfgang P. Fendler, Manuel Weber, Amir Iravani, Michael S. Hofman, Jérémie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Eric J. Small, Matthew R. Smith, (unknown), Thomas A. Hope, Isabel Rauscher, Anil Londhe, Angela Lopez‐Gitlitz, Shinta Cheng, Tobias Maurer, Ken Herrmann, Matthias Eiber, Boris Hadaschik	183
19	FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy 2012 ·Cancer Research ·Zhoulei Li, Nicolas Graf, Ken Herrmann, (unknown), Michaela Aichler, Annette Feuchtinger, (unknown), Axel Walch, Christian Peschel, Markus Schwaiger, Andreas K. Buck, Ulrich Keller, Tobias Dechow	30
20	Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response 2008 ·Clinical Cancer Research ·Rupert Langer, Katja Ott, Katja Specht, Karen Becker, Florian Lordick, Maria Burian, Ken Herrmann, André Schrattenholz, Michael A. Cahill, Markus Schwaiger, Heinz Höfler, Hans‐Jürgen Wester	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact